Satellos Bioscience Inc. (MSLE) Key Metrics
MSLE valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $137.1M
- Enterprise value
- $121.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.0
- EV / EBITDA
- 4.7
- Dividend yield
- —
- Beta
- 1.15
MSLE key metrics, 2015–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMSLE returns How much profit the business earns on the capital it uses.
MSLE financial health Debt, liquidity and how easily interest is covered.
MSLE efficiency & capital use Working capital cycle and where the cash goes.
MSLE returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MSLE debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MSLE key metrics
2015–2025| 2025 | 2022 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Share price at fiscal year-end | $5.88 | $2.06 | $11.76 | $12.72 | $7.68 | $7.20 | $7.68 | $5.76 |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −89.5% | −339.5% | — | — | — | −73.1% | −49.2% | −47.5% |
| Return on invested capital (ROIC) | — | −465.4% | — | — | — | — | — | — |
| Return on assets (ROA) | −78.0% | −184.5% | −119.6% | −236.2% | −215.8% | −64.9% | −47.2% | −46.1% |
| Return on tangible assets | −78.0% | −502.0% | −139.4% | −132.0% | −955.6% | −90.0% | −61.3% | −46.6% |
| Financial health | ||||||||
| Total debt | — | — | $1.1M | — | — | — | — | — |
| Cash & short-term investments | $27.7M | $1.9M | $719,151 | $1.0M | $10,107 | $1.1M | $2.4M | $3.7M |
| Net debt | −$27.7M | −$1.9M | $376,631 | −$1.0M | −$10,107 | −$1.1M | −$2.4M | −$3.7M |
| Debt / assets | — | — | 0.97 | — | — | — | — | — |
| Current ratio | 7.77 | 0.79 | 5.13 | 1.81 | 0.22 | 4.77 | 17.54 | 33.01 |
| Quick ratio | 7.77 | 0.79 | 5.13 | 1.81 | 0.22 | 4.77 | 17.54 | 33.01 |
| Working capital | $27.8M | −$591,036 | $909,842 | $672,418 | −$625,671 | $1.1M | $2.3M | $3.7M |
| Invested capital | $74,000 | $1.4M | $192,380 | −$338,256 | −$632,627 | −$41,296 | −$47,445 | $26,565 |
| Tangible asset value | $27.8M | −$546,401 | −$184,252 | $678,671 | −$622,522 | $1.1M | $2.3M | $3.7M |
| Net current asset value | $27.8M | −$591,036 | −$185,942 | $672,418 | −$625,671 | $1.1M | $2.3M | $3.7M |
| Capital allocation | ||||||||
| Dividends paid | — | $0 | — | — | — | — | — | — |
| Capex / depreciation | 1.50 | 0.01 | 0.00 | 1.96 | 2.08 | — | 0.15 | 0.08 |
| Efficiency | ||||||||
| Days payables outstanding | 127,143.7 | 141.9 | — | — | — | — | — | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.00 | 2.57 | — | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $370,000 | $257,401 | $417,622 | $277,296 | $109,530 | $63,550 | $30,574 | $23,753 |
| Average payables | $1.8M | $1.5M | — | — | — | — | — | — |
| Intangibles / total assets | 0.0% | 63.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.9% | 1.1% |
Computed from MSLE's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MSLE valuation and financial ratios
Satellos Bioscience earned a return on equity of −89.5% in fiscal 2025.
See the MSLE income statement, the MSLE chart for price history, or the MSLE stock overview for the latest quote and news.
MSLE key metrics FAQ
What is Satellos Bioscience's return on equity?
Satellos Bioscience's return on equity (ROE) was −89.5% in fiscal 2025: net income of -$24.9 million on average shareholders' equity of $15.6 million.
What is Satellos Bioscience's current ratio?
Satellos Bioscience's current ratio was 7.77 at the end of fiscal 2025: current assets were 7.77 times current liabilities.